About this study
The BE SURE study is a clinical research study. It is testing whether an investigational medication called bimekizumab is safe and effective for treating moderate to severe chronic plaque psoriasis. Bimekizumab is described as investigational because it has not been approved to be prescribed by doctors and other medical professionals and is still being researched in clinical studies like this one.
- Are you 18 years of age or older?
- Do you have moderate to severe chronic plaque psoriasis?
- Have you had this condition for at least six months?
If so, you may be able to participate.
What does the study involve?
The study will compare three different treatment groups:
bimekizumab every 4 weeks throughout the study
bimekizumab every 4 weeks during the initial treatment period, then every 8 weeks through the maintenance treatment period, and
adalimumab (comparator medication) group.
Neither you nor your study doctor will decide or know to which treatment group you are assigned. This information can be made available in an emergency.
The study will last for a maximum of 77 weeks and will consist of:
- A 2-to-5-week screening period
- A 16-week initial treatment period
- A 40-week maintenance treatment period, and
- A 20-week safety follow-up period after the last dose of study medication.
If eligible, you may be able to participate in an open-label extension study after the maintenance treatment period.
To find out if you qualify, contact your nearest study center.
If you know someone who is living with moderate to severe chronic plaque psoriasis, that person may be interested in the BE SURE study.